Forecast

There is no analyst data available for this company.

News Go to news feed

Bone Biologics expects completion of patient recruitment for NB1 study by end of 2025

Bone Biologics says it expects to complete recruitment for the first-in-human NB1 study in degenerative disc disease in Australia by the end of 2025. The multicenter study of up to 30 patients compares two NB1 concentrations with autograft; NB1 combines NELL-1 with demineralized bone matrix. The company has extended product shelf life from 12 to 18 months, is targeting 24 months, and plans additional clinical sites, an improved potency assay and an interim report after all patients reach the six-month follow-up. Bone Biologics completed a $5m capital raise at the end of June, which is expected to fund operations into Q2 2026; a 1:6 reverse stock split also took effect in June. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2024, Bone Therapeutics has already paid 0,14€ in dividends. The last payout was in July 2024.

Financials

In the last quarter, Bone Therapeutics had revenue of 896,15M€ and net profit of 7,04M€

(EUR)	Jun 2026	YoY
Revenue	+896,15M	13.780,59%
Gross profit	+352,39M	11,13%
Net profit	+7,04M	87,40%
EBITDA	+45,01M	16,36%

Fundamentals

Metric	Value
Market capitalization	+3,45B€
Number of shares	329,42M
52-week high/low	+12,87€ - +8,63€
Dividends	No
Beta	0,14
P/E ratio	−6,79
PEG ratio	+0,01
P/B ratio	+1,08
P/S ratio	+0,94

Company profile

Bone Therapeutics SA ist ein Biotechnologieunternehmen, das sich mit der Entwicklung von Zelltherapieprodukten für die Orthopädie und Knochenerkrankungen befasst. Zu den Produkten des Unternehmens gehören ALLOB, ein allogenes Zelltherapieprodukt, das sich in der klinischen Phase I/IIa zur Behandlung von Frakturen mit verzögerter Knochenheilung und von Lendenwirbelfusionen befindet, sowie JTA-004, ein intraartikuläres Injektionsmittel, das sich in der klinischen Phase III zur Behandlung von osteoarthritischen Schmerzen im Knie befindet. Bone Therapeutics SA wurde im Jahr 2006 gegründet und hat seinen Sitz in Mont-Saint-Guibert, Belgien.

Name	Bone Therapeutics
CEO	Yasuhiro Ohmura
Headquarters	Tokyo, ty Belgium
Website	bonetherapeutics.com
IPO	02/06/2015
Employees	19.928

Ticker symbols

Exchange	Symbol
Euronext	BOTHE.BR
Brussels Stock Exchange	BOTHE.BR
Düsseldorf	BT1.DU
Frankfurt	BT1.F
London	0R55.L
London Stock Exchange	0R55.L
Pnk	NINOY
Toronto Stock Exchange	TOH.V